Published in CNS Spectr on January 01, 2002
Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. Schizophr Bull (2009) 1.19
Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis. J Psychiatry Neurosci (2016) 0.90
The pNNx Heart Rate Variability Statistics: An Application to Neuroautonomic Dysfunction of Clozapine-Treated Subjects. Psychiatry Investig (2009) 0.83
Dose-dependent effect of antipsychotic drugs on autonomic nervous system activity in schizophrenia. BMC Psychiatry (2012) 0.78
Cardiac risk and schizophrenia. J Psychiatry Neurosci (2005) 0.77
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci (2002) 2.69
Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry (2004) 2.23
Computerized experience sampling method (ESMc): assessing feasibility and validity among individuals with schizophrenia. J Psychiatr Res (2005) 2.06
The role of executive functioning in CBT: a pilot study with anxious older adults. Behav Res Ther (2005) 1.97
Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry (2006) 1.79
Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry (2005) 1.71
Paternal age and risk of schizophrenia in adult offspring. Am J Psychiatry (2002) 1.69
Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry (2009) 1.65
The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry (2004) 1.59
Resting neural activity distinguishes subgroups of schizophrenia patients. Biol Psychiatry (2004) 1.51
Paternal age and sporadic schizophrenia: evidence for de novo mutations. Am J Med Genet (2002) 1.47
Diagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms. Am J Psychiatry (2010) 1.46
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord (2013) 1.46
The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull (2005) 1.42
Neuropsychological differences between late-onset and recurrent geriatric major depression. Am J Psychiatry (2005) 1.41
Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res (2002) 1.40
Facial expressiveness in patients with schizophrenia compared to depressed patients and nonpatient comparison subjects. Am J Psychiatry (2005) 1.39
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry (2002) 1.29
Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry (2007) 1.25
Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. J Consult Clin Psychol (2007) 1.21
Visual backward-masking deficits in schizophrenia: relationship to visual pathway function and symptomatology. Schizophr Res (2003) 1.19
Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J (2005) 1.18
Use of Palm computer as an adjunct to cognitive-behavioural therapy with an ultra-high-risk patient: a case report. Early Interv Psychiatry (2008) 1.17
Schizophrenia risk and paternal age: a potential role for de novo mutations in schizophrenia vulnerability genes. CNS Spectr (2002) 1.17
Odor identification, eye tracking and deficit syndrome schizophrenia. Biol Psychiatry (2002) 1.15
Developing novel treatments for mood disorders: accelerating discovery. Biol Psychiatry (2002) 1.13
A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry (2003) 1.10
Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy. J Clin Psychiatry (2008) 1.10
Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. Psychiatry Res (2011) 1.09
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry (2005) 1.07
Families' experience with seeking treatment for recent-onset psychosis. Psychiatr Serv (2009) 1.07
Diphenoxylate hydrochloride dependency. J Psychiatr Pract (2007) 1.07
Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol (2012) 1.06
Olfactory identification and WAIS-R performance in deficit and nondeficit schizophrenia. Schizophr Res (2004) 1.06
Stigma in families of individuals in early stages of psychotic illness: family stigma and early psychosis. Early Interv Psychiatry (2009) 1.06
Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depress Anxiety (2009) 1.01
Childhood trauma and prodromal symptoms among individuals at clinical high risk for psychosis. Schizophr Res (2009) 1.01
Symptoms of posttraumatic stress disorder in patients who have had a myocardial infarction. Psychosomatics (2006) 1.00
Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry (2003) 0.99
Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand. CNS Spectr (2005) 0.99
Molecular targets in the treatment of anxiety. Biol Psychiatry (2002) 0.99
Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry (2004) 0.98
Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry (2007) 0.98
Source monitoring impairments in schizophrenia: characterisation and associations with positive and negative symptomatology. Psychiatry Res (2002) 0.98
Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry (2007) 0.97
Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdala. Biol Psychiatry (2003) 0.97
Insight into illness in patients with mania, mixed mania, bipolar depression and major depression with psychotic features. Bipolar Disord (2002) 0.97
Early-life stress, corticotropin-releasing factor, and serotonin transporter gene: a pilot study. Psychoneuroendocrinology (2010) 0.96
Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res (2011) 0.96
The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. Neurosci Lett (2010) 0.96
The human dimension: how the prefrontal cortex modulates the subcortical fear response. Rev Neurosci (2007) 0.95
Does maintenance CBT contribute to long-term treatment response of panic disorder with or without agoraphobia? A randomized controlled clinical trial. J Consult Clin Psychol (2012) 0.95
A brief smell identification test discriminates between deficit and non-deficit schizophrenia. Psychiatry Res (2003) 0.94
Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. J Consult Clin Psychol (2005) 0.93
Citalopram-induced diplopia. Psychosomatics (2005) 0.93
Patient characteristics and variability in adherence and competence in cognitive-behavioral therapy for panic disorder. J Consult Clin Psychol (2013) 0.93
Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry (2012) 0.93
An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. Biol Psychiatry (2002) 0.93
Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety (2011) 0.93
Effect of medication and psychotherapy on heart rate variability in panic disorder. Depress Anxiety (2009) 0.92
Early-life stress and neurometabolites of the hippocampus. Brain Res (2010) 0.92
Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res (2004) 0.92
Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. Am J Psychiatry (2005) 0.91
Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res (2003) 0.91
Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV. Curr HIV/AIDS Rep (2006) 0.91
Advances in the treatment of anxiety: targeting glutamate. NeuroRx (2006) 0.90
Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry (2004) 0.90
Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. Psychoneuroendocrinology (2002) 0.89
The neurobiology of postpartum depression. CNS Spectr (2005) 0.89
Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry (2006) 0.89
Rater bias in a blinded randomized placebo-controlled psychiatry trial. Stat Med (2006) 0.89
Attrition in a multicenter clinical trial for panic disorder. J Nerv Ment Dis (2010) 0.88
Pathways Associating Childhood Trauma to the Neurobiology of Schizophrenia. Front Psychol Behav Sci (2014) 0.88
Delusions in individuals with schizophrenia: factor structure, clinical correlates, and putative neurobiology. Psychopathology (2005) 0.88
Antidepressant adherence and suicide risk in depressed youth. Am J Psychiatry (2005) 0.88
"Attenuated psychotic symptoms syndrome" as a risk syndrome of psychosis, diagnosis in DSM-V: The debate. Indian J Psychiatry (2011) 0.88
Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Res (2006) 0.87
Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr (2004) 0.86
Auditory abnormalities in autism: toward functional distinctions among findings. CNS Spectr (2005) 0.86
Childhood onset diagnoses in a case series of teens at clinical high risk for psychosis. J Child Adolesc Psychopharmacol (2009) 0.86
Childhood abuse, nonadherence, and medical outcome in pediatric liver transplant recipients. J Am Acad Child Adolesc Psychiatry (2007) 0.85
Maternal household crowding during pregnancy and the offspring's risk of schizophrenia. Schizophr Res (2006) 0.85
Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J Psychiatr Pract (2007) 0.85
Odor identification impairments in schizophrenia: relationship with demographic measures, clinical variables, and diagnostic subtypes. CNS Spectr (2002) 0.85
Are cognitive symptoms of schizophrenia mediated by abnormalities in emotional arousal? CNS Spectr (2002) 0.85
Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrations. Ann N Y Acad Sci (2006) 0.85
Novel treatment approaches for refractory anxiety disorders. Depress Anxiety (2008) 0.84